Drug Trial Radar · NCT03493685
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
371
Actual
Start
Apr 17, 2018
Primary completion
Mar 20, 2023
Study completion Mar 19, 2026
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Conditions
- Focal Segmental Glomerulosclerosis
Interventions
sparsentanDrug
Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
IrbesartanDrug
target dose of 300 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Slope of Estimated Glomerular Filtration Rate (eGFR)Time frame: From Day 1 to Week 108
- Percentage of Participants Achieving FSGS Partial Remission Endpoint (FPRE)Time frame: Week 36
Locations
226 sites in 22 countries. Site status is shown where the registry gives one.
Travere Investigational Site
Mesa, Arizona
Travere Investigational Site
Phoenix, Arizona
Travere Investigational Site
Los Angeles, California
Travere Investigational Site
Northridge, California
Travere Investigational Site
Palo Alto, California
Travere Investigational Site
San Diego, California
Travere Investigational Site
San Dimas, California
Travere Investigational Site
San Francisco, California
Travere Investigational Site
Torrance, California
Travere Investigational Site
Victorville, California
Travere Investigational Site
Denver, Colorado
Travere Investigational Site
Denver, Colorado
Travere Investigational Site
Middlebury, Connecticut
Travere Investigational Site
Wilmington, Delaware
Travere Investigational Site
Washington D.C., District of Columbia
Travere Investigational Site
Coral Springs, Florida
Travere Investigational Site
Fort Lauderdale, Florida
Travere Investigational Site
Gainesville, Florida
Travere Investigational Site
Miami, Florida
Travere Investigational Site
Miami, Florida
Travere Investigational Site
Miami, Florida
Travere Investigational Site
Ocala, Florida
Travere Investigational Site
Orlando, Florida
Travere Investigational Site
Port Charlotte, Florida
Travere Investigational Site
Temple Terrace, Florida
Travere Investigational Site
Winter Park, Florida
Travere Investigational Site
Lawrenceville, Georgia
Travere Investigational Site
Nampa, Idaho
Travere Investigational Site
Chicago, Illinois
Travere Investigational Site
Hinsdale, Illinois
Travere Investigational Site
Kansas City, Kansas
Travere Investigational Site
Wichita, Kansas
Travere Investigational Site
Louisville, Kentucky
Travere Investigational Site
Monroe, Louisiana
Travere Investigational Site
New Orleans, Louisiana
Travere Investigational Site
Shreveport, Louisiana
Travere Investigational Site
Boston, Massachusetts
Travere Investigational Site
Springfield, Massachusetts
Travere Investigational Site
Ann Arbor, Michigan
Travere Investigational Site
Detroit, Michigan
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.